國家衛生研究院 NHRI:Item 3990099045/9374
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 857830      在线人数 : 836
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9374


    题名: Renoprotective effect of combining pentoxifylline with renin-angiotensin-aldosterone system blockade in pre-dialyzed advanced chronic kidney disease patients - a ntionwide database analysis
    作者: Kuo, KL;Hung, SC;Liu, JS;Chang, YK;Hsu, CC;Tarng, DC
    贡献者: Division of Health Services and Preventive Medicine;Division of Geriatric Research
    摘要: ntroduction and Aims: Pentoxifylline has been shown to decrease proteinuria in patients with glomerular disease because it has anti-inflammatory and anti-fibrotic properties. A combination therapy of pentoxifylline with angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) could decrease proteinuria and glomerular filtration rate (GFR) decline in early chronic kidney disease (CKD). Whether the add-on pentoxifylline to ACEI/ARB provides additional benefits on renal outcome or survival remain unclear in CKD stage 5 patients who have not yet received dialysis (CKD 5 ND). Methods: A prospective cohort study was conducted based on the Taiwan National Health Insurance Research Database. From January 1, 2000, to June 30, 2009, we enrolled 10,027 CKD 5 ND patients who had serum creatinine levels >6 mg/dL and hematocrit levels <28% and who were treated with erythropoiesis-stimulating agents (ESAs) and ACEI/ARB. All patients were further divided into two groups with or without pentoxifylline within 90 days after starting ESA therapy. Patient follow-up took place until dialysis, death before initiation of dialysis or December 31, 2009. Results: In a median follow-up of 8 months, 7168 patients (71.5%) required long-term dialysis and 1853 (18.5%) died before progression to end-stage renal disease requiring dialysis. After propensity score-matching, use of pentoxifylline was associated with a lower risk for long-term dialysis (HR, 0.91; 95% CI, 0.85-0.98) and the composite outcome of long-term dialysis or death (HR, 0.92; 95% CI, 0.86-0.98), but the effect on death was marginal (HR, 0.93; 95% CI, 0.81-1.07). The renal benefit of pentoxifylline use was consistent across most patient subgroups, as was that of ARB monotherapy. Conclusions: Use of pentoxifylline was associated with lower risk for long-term dialysis by 9% in CKD 5 ND patients who received ACEI/ARB. This benefit does not increase the risk of all-cause mortality.
    日期: 2015-05
    關聯: Nephrology Dialysis Transplantation. 2015 May;30(Suppl. 3):Abstract number FP343.
    Link to: http://dx.doi.org/10.1093/ndt/gfv175.25
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0931-0509&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000361215100392
    显示于类别:[許志成] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000361215100392.pdf24KbAdobe PDF519检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈